Filing Flows › Comparisons › KRSA vs PRPH
Korsana Biosciences vs ProPhase Labs: KRSA and PRPH compared
Korsana Biosciences is the larger company: $1.0M of revenue in its latest quarter (Q4 2025) against $1.0M for ProPhase Labs (Q2 2026). ProPhase Labs is growing faster (-19% against -43% a year earlier). Korsana Biosciences is more profitable, with an operating margin of -81.8% against -261.6%.
Where the money goes: KRSA and PRPH
Korsana Biosciences (KRSA) · Q4 2025
Korsana Biosciences, Q4 2025: revenue $1.0M (-43% year over year), operating margin -81.8%, net loss $799K, operating cash flow −$1.6M. The chart follows the revenue to costs, profit and cash.
ProPhase Labs (PRPH) · Q2 2026
ProPhase Labs, Q2 2026: revenue $1.0M (-19% year over year), operating margin -261.6%, net loss $3.1M, operating cash flow −$78K. The chart follows the revenue to costs, profit and cash.
| Korsana Biosciences (KRSA) | ProPhase Labs (PRPH) | |
|---|---|---|
| Latest quarter | Q4 2025 | Q2 2026 |
| Revenue | $1.0M | $1.0M |
| Revenue growth, Y/Y | -43% | -19% |
| Operating margin | -81.8% | -261.6% |
| Net earnings | −$799K | −$3.1M |
| Net margin | -78.0% | -301.8% |
| Operating cash flow | −$1.6M | −$78K |
Questions
Which is bigger, Korsana Biosciences or ProPhase Labs?
Korsana Biosciences is the larger company: $1.0M of revenue in its latest quarter (Q4 2025) against $1.0M for ProPhase Labs (Q2 2026).
Is Korsana Biosciences or ProPhase Labs growing faster?
ProPhase Labs is growing faster (-19% against -43% a year earlier).
Which is more profitable, Korsana Biosciences or ProPhase Labs?
Korsana Biosciences is more profitable, with an operating margin of -81.8% against -261.6%.
More: Korsana Biosciences earnings · how Korsana Biosciences makes money · ProPhase Labs earnings · how ProPhase Labs makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 30, 2026; 10-Q filed Aug 19, 2026). Fiscal quarters can end on different dates. Not investment advice.